Development of patch and spray formulations for enhancing topical delivery of sinomenine hydrochloride

Journal of Pharmaceutical Sciences

Volumn 99, Issue 4, 2010, Pages 1790-1799

  Li, Xinru ^a   Li, Xiaoyan ^a   Zhou, Yanxia ^a   Liu, Yan ^a,b   Guo, Ming ^b   Zhu, Qingfen ^b   Xie, Yuanchao ^b   Fan, Zhiyun ^b  

^a PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

^b Shandong Institute for Drug Control   (China)

Author keywords

Log P; Patch; Percutaneous; Pharmacodynamics; Pharmacokinetics; Physicochemical properties; Sinomenine hydrochloride; Spray

Indexed keywords

FREUND ADJUVANT; PENETRATION ENHANCING AGENT; SINOMENINE;

AEROSOL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG DOSAGE FORM COMPARISON; DRUG DOSE INCREASE; DRUG FORMULATION; DRUG MEGADOSE; DRUG PENETRATION; DRUG QUALITY; DRUG SAFETY; DRUG SOLUBILITY; LOW DRUG DOSE; MALE; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; PH; RAT; RHEUMATOID ARTHRITIS; SKIN IRRITATION;

EID: 77949780455     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.21947     Document Type: Article

References (40)

1. Gordon DA, Hastings DE. 2003. Clinical features of rheumatoid arthritis. In: Hochberg MC, Silman AJ, Smolen JS, Weinblatt ME, Weisman MH, editors. Rheumatology. 3rd edition. New York, NY: Mosby. pp. 765-780.
2. Mitchell DM, Spitz PW, Young DY, Bloch DA, McShane DJ, Fries JF. 1986. Survival, prognosis, and causes of death in rheumatoid arthritis. Arthritis Rheum 29:706-714.
3. Pincus T, Callahan LF, Sale WG, Brooks AL, Payne LE, Vaughn WK. 1984. Severe functional declines, work disability, and increased mortality in seventy-five rheumatoid arthritis patients studied over nine years. Arthritis Rheum 27:864-872.
4. Leigh JP, Fries JF, Parikh N. 1992. Severity of disability and duration of disease in rheumatoid arthritis. J Rheumatol 19:1906-1911.
5. Eberhardt k, Larsson BM, Nived k. 1993. Early rheumatoid arthritis, some social, economic, and psychological aspects. Stand J Rheumatol 22:119-123.
6. Langer R. 2004. Transdermal drug delivery: Past progress, current status, and future prospects. Adv Drug Deliv Rev 56:557-558.
7. Thomas BJ, Finnin BC. 2004. The transdermal revolution. Drug Discov Today 9:697-703.
8. Liu L, Riese J, Resch K, Kaever V. 1994. Impairment of macrophage eicosanoid and nitric oxide production by an alkaloid from sinomenine acutum. Arzneimittelforschung 44:1223-1226.
9. Liu L, Buchner E, Beitze D, Schmidt-Weber CB, Kaever V, Emmrich F. 1996. Amelioration of rat experimental arthritides by treatment with the alkaloid sinomenine. Int J Immunopharmacol 18: 529-543.
10. Wang MH, Chang CK, Cheng JH, Wu HT, Li YX, Cheng JT. 2008. Activation of opioid m-receptor by sinomenine in cell and mice. Neurosci Lett 443:209-212.
11. Candinas D, Mark W, Kaever V, Miyatake T, Koyamada N, Hechenleitner P. 1996. Immunomodulatory effects of the alkaloid sinomenine in the high responder ACI-to-Lewis cardiac allograft model. Transplantation 62:1855-1860.
12. Mark W, Schneeberger S, Seiler R, Stroka DM, Amberger A, Offner F, Candinas D, Margreiter R. 2003. Sinomenine blocks tissue remodeling in a rat model of chronic cardiac allograft rejection. Transplantation 75:940-945.
13. Shu L, Yin W, Zhang J, Tang B, Kang YX, Ding F, Hua ZC. 2007. Sinomenine inhibits primary CD4p T-cell proliferation via apoptosis. Cell Biol Int 31: 784-789.
14. Zhao Y, Li J, Yu K, Liu Y, Chen X. 2007. Sinomenine inhibits maturation of monocyte-derived dendritic cells through blocking activation of NF-kappa B. Int Immunopharmacol 7:637-645.
15. Kondo Y, Takano F, Yoshida K, Hojo H. 1994. Protection by sinomenine against endotoxin-induced fulminant hepatitis in galactosaminesensitized mice. Biochem Pharmacol 48:1050-1052.
16. Maricic N, Ehrlich K, Gretzer B, Schuligoi R, Respondek M, Peskar B. 1999. Selective cyclo-oxygenase2-inhibitors aggravate ischaemia-reperfusion injury in the rat stomach. Br J Pharmacol 128:1659-1666.
17. Reuben SS, Steinberg R. 1999. Gastric perforation associated with the use of celecoxib. Anesthesiology 91:1548-1549.
18. Bosch-Marce M, Claria J, Titos E, Masferrer JL, Altuna R, Poo JL, Jim enez W, Arroyo V, Rivera F, Rodes J. 1999. Selective inhibition of cyclooxygenase 2 spares renal function and prostaglandin synthesis in cirrhotic rats with ascites. Gastroenterology 116:1167-1175.
19. Fu SX, Zhang SS, Li YS. 1963. Pharmacological effect of sinomenine. II. Toxicity and the general pharmacological effects. Acta Pharm Sinica [Chinese] 10:673-676.
20. Ye MR, Liu L, Zeng YE, Zhang LQ, Tan YH, Deng SJ, Huang GY. 2001. Studies on the relationship between sinomenine distribution and its organic toxicology. Chin Pharmacol Bull [Chinese] 17:65-69.
21. Wang J, Ruan J, Zhang C, Ye Y, Cai Y, Wu Y. 2008. Development and evaluation of the Sinomenine transdermal patch. Pak J Pharm Sci 21:407-410.
22. Zhang XZ, Zhu HD, Meng SF, Pan XG. 2007. Preparation of sinomenine microemulsion and its transdermal absorption. Zhongguo Zhong Yao Za Zh [Chinese] 32:2007-2010.
23. Wang Y, Zhou L, Ling J. 2005. Effect of penetration enhancers on the transdermal penetration of sinomenine liposome patch. Zhong Yao Cai [Chinese] 28:567-570.
24. Zhang N, Xu L, Xu P, Zhong G. 2002. Study on the permeability of 125I-sinomenine via the transdermal delivery way in rats. Zhong Yao Cai [Chinese] 25:412-413.
25. Dias CS, Anand BS, Mitra AK. 2001. Effect of monoand di-acylation on the ocular disposition of ganciclovir: Physicochemical properties, ocular bioreversion, and antiviral activity of short chain ester prodrugs. J Pharm Sci 91:660-668.
26. Krisztina AT, Alex A, Karl JB, Benjamin P, György S. 1994. Determination of protonation macro- and microconstants and octanol/water partition coefficient of the antiinflammatory drug niflumic acid. J Pharm Biomed Anal 12:1369-1377.
27. Su DS, Wang SL. 2004. Partition of drug between oil and water. In: Yu XJ, Sun XF, editors. Physical pharmacy [Chinese]. 1st edition. Beijing: China Chemical Industry Press. pp. 97-102.
28. Thorbecke GJ, Schwarcz R, Leu J, Huang C, Simmons WJ. 1999. Modulation by cytokines of oral tolerance to type II collagen. Arthritis Rheum 42: 110-118.
29. Vlasses PH, Ribeiro LGT, Rotmensch HH, Bondi JV, Loper AE, Hichens M, Dunlay MC, Ferguson RK. 1985. Initial evaluation of transdermal timolol: Serum concentrations and b-blockade. J Cardiovasc Pharmacol 7:245-250.
30. Gorukanti SR, Li L, Kim KH. 1999. Transdermal delivery of antiparkinsonian agent, benztropine. I. Effect of vehicles on skin permeation. Int J Pharm 192:159-172.
31. Ottiger C, Wunderli-Allenspach H. 1997. Partition behaviour of acids and bases in a phosphatidylcholine liposome-buffer equilibrium dialysis system. Eur J Pharm Sci 5:223-231.
32. de Paula E, Schreier S. 1995. Use of a novel method for determination of partition coefficients to compare the effect of local anesthetics on membrane structure. Biochim Biophys Acta 1240:25-33.
33. Diez I, Colom H, Moreno J, Obach R, Peraire C, Domenech J. 1991. A comparative in vitro study of transdermal absorption of a series of calcium channel antagonists. J Pharm Sci 80:931-934.
34. Bonina FP, Montenegro L, DeCapraris P, Bousquet E, Tirendi S. 1991. 1-Allylazacycloalkan-2-one esters as prodrugs of indomethacin for improved delivery through human skin. Int J Pharm 77:21-29.
35. Martin A, Wu PL, Adjei A, Beerbower A, Prausnitz JM. 1981. Extended Hansen solubility approach: Naphthalene in individual solvents. J Pharm Sci 70:1260-1264.
36. Chien YW, Xu H, Chiang CC, Hung YC. 1988. Transdermal controlled administration of indomethacin: I. Enhancement of skin permeability. Pharm Res 5:103-106.
37. Friend D, Catz P, Heller J, Reid J, Baker R. 1988. Transdermal delivery of levonorgestrel: I. Alkanols as permeation enhancers in vitro. J Control Release 7:243-250.
38. Howser RL. 1995. What you need to know about corticosteroid therapy. Am J Nurs 95:44-49.
39. Berner B, Mazzenga GC, Gargiulo PM, Steffens R. 1992. A transdermal nicotine system: Feasibility studies. J Control Release 20:13-19.
40. Cargill R, Engle K, Rork G, Caldwell LJ. 1986. Systemic delivery of timolol after dermal application: Transdermal flux and skin irritation potential in the rat and dog. Pharm Res 3:225-229.